



## Supporting Information

for

### **Long oligodeoxynucleotides: chemical synthesis, isolation via catching-by-polymerization, verification via sequencing, and gene expression demonstration**

Yipeng Yin, Reed Arneson, Alexander Apostle, Adikari M. D. N. Eriyagama, Komal Chillar, Emma Burke, Martina Jahfetson, Yinan Yuan and Shiyue Fang

*Beilstein J. Org. Chem.* **2023**, *19*, 1957–1965. [doi:10.3762/bjoc.19.146](https://doi.org/10.3762/bjoc.19.146)

### **Experimental details, ODN sequences, PCR primers, and sequence alignments**

## Table of contents

Experimental section	S2–S5
ODN sequences	S6
Primer sequences	S7
Sequence alignments	S8–S11
References	S11

## Experimental section

**General information:** ODNs were synthesized on an ABI 394 DNA/RNA synthesizer. PCRs were performed using an Applied Biosystems 2720 Thermal Cycler. Gel images were obtained on a UVP GelDoc-IT Imaging System 2UV Transilluminator at 302 nm. Compounds **1b** and **2** were synthesized following reported procedures [1,2]. Reagents for ODN synthesis were purchased from Glen Research and Hongene Biotech. Other small molecule chemicals such as DBU, saturated NH<sub>4</sub>OH, *N,N*-dimethylacrylamide, *N,N'*-methylenebisacrylamide, ammonium persulfate, and *N,N,N',N'*-tetramethylethylenediamine (TMEDA) were purchased from Aldrich or other chemical companies. Authentic GFP gene and primers were purchased from IDT. GelRed® was purchased from Biotium. Solid-phase reversible immobilization (SPRI) bead (cat# CNGS005) was purchased from BullDog Bio. QIAprep® Spin Miniprep Kit, and QIAquick® Gel Extraction Kit were purchased from Qiagen. dNTPs, Phusion Hot Start II High Fidelity DNA polymerase (cat# F549S), DreamTaq™ Hot Start Green PCR Master Mix (cat # K9021), and Zero Blunt™ TOPO™ PCR Cloning Kit (cat# 450031) were purchased from ThermoFisher. LB was purchased from Sigma-Aldrich. PmeI and SgfI restriction enzymes, pF1k T7 Flexi® vector (cat# C8451), and Single Step (KRX) Competent Cells (cat# L3002) were purchased from Promega. SOC medium (cat # B8020S), NEBuilder® HiFi DNA Assembly kit (cat # E5520S), and NEB® 5-alpha cells (cat # C2987H) were purchased from New England Biolab. L-Rhamnose monohydrate (cat # R-105-50) was purchased from GoldBio. Sanger sequencing was carried out at Azenta Life Sciences/Genewiz.

**Chemical synthesis of long ODNs:** The 800-mer GFP gene construct (all sequences are given in this supporting information) was divided into a 399 and 401 nt ODNs. They were synthesized using phosphoramidite chemistry in commercial CPG columns (0.2 μmol, 2000 Å). Before the synthesis, the columns were subject to capping conditions (see below) for 20 min. The loading of the columns was reduced to 0.1 μmol using a solution containing 0.05 M 5'-DMTr-dT amidite (**1a**) and 0.05 M 5'-Bz-dT amidite (**1b**) for the coupling step in the first synthetic cycle. Deblocking: DCA (2% in DCM), 98 s. Coupling: Bz-dA, Ac-dC, iBu-dG or dT amidite (0.1 M in ACN); DCI (0.25 M in ACN), 2.5 s × 2 reagent delivery, 35 s waiting. Capping: Cap A, THF/pyridine/acetic anhydride; cap B, 1-methylimidazole (16% in THF), 10 s delivery, 10 s waiting. Oxidation: I<sub>2</sub> (0.02 M in THF/pyridine/H<sub>2</sub>O), 8 s delivery, 15 s waiting. The last nucleotide was incorporated with the polymerizable tagging amidite **2** (0.1 M in ACN, 0.25 M DCI in ACN, 5 min × 3; followed by capping and oxidation as usual; no detritylation). The CPG was divided into 10 equal portions. Deprotection and cleavage: To one portion of the CPG (theoretically 10 nmol ODN) in a 1.5 mL centrifuge tube was added DBU (10% in ACN). The tube was gently shaken at rt for 10 min. The supernatant was removed, and the DBU treatment was repeated one time. Saturated NH<sub>4</sub>OH (0.5 mL) was added. The tube was sealed and heated at 60 °C overnight. After cooling to rt, the supernatant was transferred to a clean centrifuge tube. The CPG was washed with water (200 μL × 3). The supernatant and washes were combined, and the volume was adjusted to 200 μL by evaporation and dilution; 50 μL were used in the next steps.

**Purification of long ODNs using catching-by-polymerization (CBP):** Polymerization: To the 50 μL ODN solution containing **3** and **4** (Scheme 1) as well as other materials (theoretically 2.5 nmol ODN) in a 1.5 mL centrifuge tube were added 12 μL polymerization solution (*N,N*-dimethylacrylamide, 340.5 μL, 3.32 mmol; *N,N'*-methylenebisacrylamide, 17 mg, 0.11 mmol; sodium acrylate, 3 mg, 0.032 mmol; and water, 170.5 μL). After mixing, ammonium persulfate (0.23 M, 5 μL) and *N,N,N',N'*-tetramethylethylenediamine (TMEDA, 0.69 M, 5 μL) were added. The tube was closed and the content was quickly mixed with a short vortex and spin, and let stand at rt for 1 h. Washing: The gel (≈ 100 μL in size) was transferred into a 50 mL centrifuge tube. NaOAc solution (20%, pH unadjusted, 20 mL) was added.

The mixture was gently shaken at rt overnight. The gel was taken to another 50 mL centrifuge tube, and Et<sub>3</sub>N solution (5%, 20 mL) was added. The tube was shaken at rt overnight. The gel was taken out, placed into a 2 mL centrifugal filter unit over the filter, and cut into small pieces using a spatula. The gel was washed with water (0.5 mL × 5). **Cleavage:** Minimum AcOH (80%, ≈ 200 μL) that could cover the gel was added. The mixture was incubated at rt for 5 min with occasional shaking. The liquid and gel were separated by centrifugation. The liquid was diluted with water (800 μL). The acid treatment was repeated two times. The gel was washed with water (0.3 mL × 3). The bottom of the filtering unit holding the gel was stopped with parafilm, and to the gel was added water (500 μL). The mixture was shaken at rt overnight. The solution and gel was separated by centrifugation, and the gel was washed with water (250 μL × 2). These gave ODN solutions in five tubes (≈ 1 mL each). The solutions were concentrated, combined, and evaporated to dryness. **Precipitation:** To the ODN was added NH<sub>4</sub>OH (saturated, 50 μL). After mixing by a short vortex and spin, *n*-BuOH (450 μL) was added. The content was mixed with a vortex (≈ 20 s), and then centrifuged at 14.5k rpm (14.1kg) for 5 min. The supernatant was removed. The precipitated ODN (theoretically 2.5 nmol ODN) was dissolved in water (200 μL). The solution was divided into four equal portions, and all were diluted to 200 μL (theoretically 0.625 nmol). This gave the solutions of CBP-purified ODN. A portion of the solution (5 μL out of 200 μL, theoretically 15.625 pmol) was quantified to have about 40 ng ODN with a Qubit fluorometer. The cleavage and precipitation steps should be carried out within one day to avoid potential ODN damage under acidic conditions.

**Conversion of long ODNs to dsODNs using PCR:** The mixture of CBP-purified ODN (399 or 401 nt, 0.5 out of 200 μL, theoretically 1.5625 pmol, ≈ 20 ng as measured with UV), Phusion Hot Start II High Fidelity DNA polymerase (0.4 U), forward and reverse primers (**s1a-b** for 399 nt ODN, **s1c-d** for 401 nt ODN, 0.5 μM), HF buffer (1×), dNTPs (0.2 mM), and nuclease-free water (20 μL total mixture volume, concentrations were final) was subjected to the following touchdown PCR (TD-PCR) cycles. For the 399 nt ODN: 98 °C for 1 min for initial denaturing; 98 °C for 7 s, 70 °C (1 °C lower for each of the nine subsequent cycles) for 15 s, and 72 °C for 20 s for 10 cycles; 98 °C for 7 s, 60 °C for 15 s, and 72 °C for 20 s for 25 cycles; and 72 °C for 7 min. For the 401 nt ODN: 98 °C for 1 min for initial denaturing; 98 °C for 7 s, 68.2 °C (1 °C lower for each of the nine subsequent cycles) for 15 s, and 72 °C for 20 s for 10 cycles; 98 °C for 7 s, 58.2 °C for 15 s, and 72 °C for 20 s for 25 cycles; and 72 °C for 7 min.

**Sequence analysis by comparing with authentic dsODNs:** Authentic 399 and 401 bp dsODNs were obtained with PCR using commercial 800 nt GFP gene (10 ng for each reaction) as template, and **s1a-b** (for 399 nt ODN) and **s1c-d** (for 401 nt ODN) as primers, under the same conditions for converting the 399 and 401 nt ssODNs to dsODNs. The PCR products from the synthesized 399 and 401 nt ODN templates were compared with the authentic ODNs using agarose gel (1%) electrophoresis (GelRed® staining). Gel images are given in Figures 2A-B.

**ODN cloning and sequencing:** The PCR products of the 399 and 401 nt ODNs (45 μL out of 60 μL from three 20 μL PCR reactions) were purified with solid-phase reversible immobilization (SPRI) beads following the manufacturer's recommended procedure using a ratio of bead/sample of 1:1 (v/v). The ODNs were eluted from the beads with water (20 μL). A portion (4 μL) was used for incorporating the ODNs into pCR<sup>TM</sup>4Blunt-TOPO<sup>TM</sup> vector using Zero Blunt<sup>TM</sup> TOPO<sup>TM</sup> PCR Cloning Kit (the kit allows blunt-end ligation) following the manufacturer's protocol. This gave a 6 μL vector solution. A portion (4 μL) was used to transform NEB<sup>®</sup> 5-alpha cells. The cells were plated on an agar plate containing 50 μg/mL kanamycin and grown overnight. Colony PCR with M13 primers (**s1k-l**) was performed over selected colonies that grew to amplify the insert cloned into the vector. The PCR products were analyzed on a 2% agarose gel (Figure 3). Three colonies for each of the 399 and 401 bp ODN cases that were among the ones having the shortest migration distance were selected for Sanger sequencing. For this purpose, the selected

colonies were cultured in LB containing 50 µg/mL kanamycin with shaking at 225 rpm at 37 °C overnight. Plasmid DNAs were extracted with QIAprep® Spin Miniprep Kit following the manufacturer's protocol, and submitted for Sanger sequencing. Forward and reverse reads were obtained using the M13 forward (**s1k**) and M13 reverse (**s1l**) primers, respectively. Forward and reverse reads were assembled into a single contig using the Cap3 program (<https://doua.prabi.fr/software/cap3>). These contigs were aligned to the reference sequence using BLAST alignment software, and aligned all together with a reference sequence using CLUSTAL Omega (see this supporting information for sequence alignments).

**Construction of GFP gene:** Gibson assembly was used to assemble the 399 and 401 bp dsODNs, which code the GFP expression construct, into the pF1k T7 Flexi® expression vector. *Expression vector preparation:* For cutting the pF1k T7 Flexi® vector with the PmeI and SgfI restriction enzymes, the mixture of nuclease-free water (10.5 µL), 5× Flexi buffer (4 µL), Flexi enzyme blend (0.5 µL), and pF1k T7 Flexi® vector (5 µL, 500 ng) was incubated at 37 °C for 2 h. DNA loading dye (6x, 5 µL) was added, and the mixture was heated at 65 °C for 10 min to stop the reaction. The entire content was loaded onto a 1% agarose gel for electrophoresis. The gel was stained with GelRed®. The bands corresponding to ≈ 3.1k bp were cut and purified using QIAquick® Gel Extraction Kit. The product was stored at -80 °C until use. *GFP gene ODN fragments preparation:* The plasmids containing the confirmed 399 and 401 bp ODNs were subjected to PCR using primers **s1e-f** and **s1g-h**, respectively. High Fidelity (HF) buffer (1×), dNTPs (0.2 mM, all concentrations were final), forward primer (**s1e** or **s1g**, 0.5 µM), reverse primer (**s1f** or **s1h**, 0.5 µM), plasmid (15 ng), and Phusion Hot Start II High Fidelity DNA polymerase (0.4 U) were mixed, and the volume was brought to 20 µL with nuclease-free water. For both of the 399 and 401 bp ODN cases, PCR cycles were 98 °C for 30 s for initial denaturing; 98 °C for 7 s, 66.6 °C for 15 s, and 72 °C for 20 s for 33 cycles; 72 °C for 7 min for one cycle; held at 8 °C. The product was loaded onto a 1% agarose gel for electrophoresis. The bands corresponding to ≈ 400 bp were cut, and the ODNs were isolated and purified using QIAquick® Gel Extraction Kit. *Gibson Assembly, cloning and Sanger sequencing:* The two GFP fragments and the restriction enzyme treated pF1k T7 Flexi® vector were combined using the NEBuilder® HiFi DNA Assembly Kit following the manufacturer's protocol. The solution of pF1K T7 vector (0.032 pmol, 75 ng), GFP ODN fragments (PCR products of 399 and 401 bp ODNs, ≈ 0.064 pmol, ≈ 16.9 ng), NEBuilder mix (10 µL), and nuclease-free water (total mixture volume 20 µL) was incubated at 50 °C for 20 min. A portion of this mix (2 µL) was used to transform the NEB® 5-alpha chemically competent cells following the manufacturer's protocol. The cells were plated on kanamycin plates and incubated at 37 °C overnight. Plasmid DNA of eight colonies was isolated using QIAprep® Spin Miniprep Kit. Colony PCR was performed using DreamTaq™ Hot Start Green PCR Master Mix with **s1i** and **s1j** as primers. The PCR products were analyzed with 2% agarose gel electrophoresis (lane 1, Figure 2C). All colonies were confirmed to contain the expected GFP gene. Two colonies were grown overnight in LB broth containing 50 µg/mL kanamycin. Plasmid DNAs were extracted using QIAprep® Spin Miniprep Kit, and were submitted for Sanger sequencing with a forward and reverse reactions for each (**s1i** and **s1j**). Sequence contigs were assembled and aligned as described above. Both clones were confirmed to contain the correct GFP sequence, and the GFP sequence is at the planned location in the expression vector (see this supporting information for sequence alignments).

**Assembly of control GFP gene into pF1k T7 Flexi® expression vector:** The authentic 800 bp GFP gene was amplified using the same PCR recipe and cycling parameters described above for the 399 and 401 bp cases using primers **s1e** and **s1h**. The PCR product was purified with gel electrophoresis, and the ODN was isolated and purified using QIAquick® Gel Extraction Kit. The gel-purified ≈ 800 bp ODN and the restriction enzyme treated pF1k T7 Flexi® vector were assembled using NEBuilder® HiFi DNA Assembly Kit with the following recipe: pF1k T7 vector (0.032 pmol), ≈ 800 bp ODN PCR product (0.064 pmol), NEBuilder mix (12 µL), and nuclease-free water (total mixture volume 24 µL). The mixture was incubated

at 50 °C for 20 min. A portion (2 µL) was transformed into NEB® 5-alpha chemically competent cells. Colony PCR using primers **s1i** and **s1j** was performed to select positive colonies containing the GFP gene. The PCR products were analyzed with 2% agarose gel electrophoresis (lane 2, Figure 2C). Several positive colonies were cultured in LB containing kanamycin (50 µg/mL) with shaking at 37 °C overnight for plasmid DNA extraction. The plasmid DNAs of two colonies were isolated with QIAprep® Spin Miniprep Kit and submitted for Sanger sequencing. Forward and reverse reads (primers **s1i** and **s1j**) were generated and assembled into contig as previously described. One sequence is correct, the other has an error (sequence alignments are provided in this supporting information file).

**Expression of GFP in *E. coli*:** The pF1k T7 Flexi® expression vector (20 ng) confirmed to contain the correct GFP gene originated from the synthetic 399 and 401 nt ODNs was transformed into Single Step (KRX) competent cells following the manufacturer's protocol. Briefly, KRX cells were thawed on ice for 5 min. After adding the expression vector into the cell, the tube was gently flicked, and incubated on ice for 20 min. The tube was heat shocked by heating at 42 °C for 20 s and cooling on ice for 5 min. SOC medium (200 µL) was added, and the tube was incubated on its side with shaking ( $\approx$  225 rpm) at 37 °C for 1 h. The cells were diluted 10 times with LB. A portion (100 µL) was plated on agar plates containing kanamycin (50 µg/mL) and incubated at 37 °C overnight. A single colony was inoculated in LB (5 mL) containing kanamycin (50 µg/mL), and grown with 275 rpm shaking at 37 °C overnight. A portion (100 µL) of the culture was plated on agar plates (50 µg/µL kanamycin) with or without rhamnose (0.5%). The plates were incubated at 37 °C overnight. Pictures (Figures 4A-B) were taken under UV light. Pictures of cells containing the correct GFP gene originated from the authentic 800 bp ODN from commercial source were obtained using the same procedure (Figures 4C-D).

## ODN sequences

Complementary sequence (i.e. antisense strand) of the entire GFP coding region plus promoter and terminator segments (800 nt ODN):

(5')TAAACCCCTCCGTTTTAGAGAGGGGTTATGCTAGTTATTTGTAGAGCTCATCCATGCCATG  
TGTAATCCCAGCAGCAGTTACAAACTCAAGAAGGACCATGTGGTCACGCTTTTCGTTGGGAT  
CTTTCGAAAGGGCAGATTGTGTCTGACAGGTAATGGTTGTCTGGTAAAAGGACAGGGCCATC  
GCCAATTGGAGTATTTTGTGATAATGGTCTGCTAGTTGAACGGATCCATCTTCAATGTTGTG  
GCGAATTTTGAAGTTAGCTTTGATTCCATTCTTTTGTCTGCTGCCGTGATGATACATTGTGT  
GAGTTATAGTTGTACTCGAGTTTGTGTCCGAGAATGTTTCCATCTTCTTTAAAATCAATACCT  
TTTAACTCGATACGATTAACAAGGGTATCACCTTCAAACCTTGACTTCAGCACGCGTCTTGTA  
GTTCCCGTCATCTTTGAAAGATATAGTGCCTTCTGTACATAACCTTCGGGCATGGCACTCTT  
GAAAAAGTCATGCCGTTTCATATGATCCGGATAACGGGAAAAGCATTGAACACCATAAGAG  
AAAGTAGTGACAAGTGTTGGCCATGGAACAGGTAGTTTTCCAGTAGTGCAAATAAATTTAAG  
GGTAAGTTTTCCGTATGTTGCATCACCTCACCTCTCCACTGACAGAAAATTTGTGCCATT  
AACATCACCATCTAATTCAACAAGAATTGGGACAACCTCCAGTGAAAAGTTCTTCTCCTTTAC  
TCATATTTTTTTCCTCCTTATACTTAAGCCCTATAGTGAGTCGTATTAATTCGC(3')

T7 Terminator (complementary strand, in red in the 800 nt ODN): (5')AAACCC.....TGCTAG(3')

Start codon (complementary strand, in yellow in the 800 nt ODN): (5')CAT(3')

Ribosomal binding site (RBS, complementary strand, in blue in the 800 nt ODN): (5')CTCCTT(3')

T7 Promotor (complementary strand, in green in the 800 nt ODN): (5')CCTATAGTGAGTCGTATTA(3')

399 nt ODN (shaded in yellow over the 800 nt ODN): (5')TAAACCC.....CAAGGG(3')

401 nt ODN (shaded in grey over the 800 nt ODN): (5')TATCAC.....ATTCGC(3')

## Primer sequences

399 nt ODN forward primer (**s1a**): TAAACCCCTCCGTTTTAGAGA

399 nt ODN reverse primer (**s1b**): CCCTTGTTAATCGTATCGAGT

401 nt ODN forward primer (**s1c**): TATCACCTTCAAACCTTGACTT

401 nt ODN reverse primer (**s1d**): GCGAATTAATACGACTCACT

Forward primer for preparing the 399 nt sequence for Gibson assembly (**s1e**): ccactagtaataattttcttaacttagt  
aaggagcgaTAAACCCCTCCGTTTTAGAGAGGG

Reverse primer for preparing the 399 nt sequence for Gibson assembly (**s1f**): AGTCAAGTTTGAAGG  
TGATACCCTTGTTAATCGTATCGAGTTAAAAGGTATTG

Forward primer for preparing the 401 nt sequence for Gibson assembly (**s1g**): CTCGATACGATTAAC  
AAGGGTATCACCTTCAAACCTTGACTTCAGCACG

Reverse primer for preparing the 401 nt sequence for Gibson assembly (**s1h**): gactctagaggatccccgggtacc  
gagctcgaattcggttGCGAATTAATACGACTCACTATAGGGCT

pF1K-T7-Seq-F (**s1i**): CGATCCCGCGAAATTAATACGA

pF1K-T7-Seq-R (**s1j**): AGACTGGGCGGTTTTATGGA

M13 F (**s1k**): GTAAAACGACGGCCAG

M13 R (**s1l**): CAGGAAACAGCTATGAC



**399 bp ODN Alignments:** (The number after “contig-399-” is the lane number in Figure 3)

Contig-399-15	TAAACCCCTCCGTTTTAGAGAGGGGTTATGCTAGTTATTTGTAGAGCTCATCCATGCCAT	60
contig-399-13	TAAACCCCTCCGTTTTAGAGAGGGGTTATGCTAGTTATTTGTAGAGCTCATCCATGCCAT	60
contig-399-26	TAAACCCCTCCGTTTTAGAGAGGGGTTATGCTAGTTATTTGTAGAGCTCATCCATGCCAT	60
399-bp-ODN-Reference	TAAACCCCTCCGTTTTAGAGAGGGGTTATGCTAGTTATTTGTAGAGCTCATCCATGCCAT *****	60
Contig-399-15	GTGTAATCCAGCAGCAGTTACAAACTCAAGAAGGACCATGTGGTCACGCTTTTCGTTGG	120
contig-399-13	GTGTAATCCAGCAGCAGTTACAAACTCAAGAAGGACCATGTGGTCACGCTTTTCGTTGG	120
contig-399-26	GTGTAATCCAGCAGCAGTTACAAACTCAAGAAGGACCATGTGGTCACGCTTTTCGTTGG	120
399-bp-ODN-Reference	GTGTAATCCAGCAGCAGTTACAAACTCAAGAAGGACCATGTGGTCACGCTTTTCGTTGG *****	120
Contig-399-15	GATCTTTCGAAAGGGCAGATTGTGTCGACG-GTAATGGTTGTCTGGTAAAAGGACAGGGC	179
contig-399-13	GATCTTTCGAAAGGGCAGATTGTGTCGACAGGTAATGGTTGTCTGGTAAAAGGACAGGGC	180
contig-399-26	GATCTTTCGAAAGGGCAGATTGTGTCGACAGGTAATGGTTGTCTGGTAAAAGGACAGGGC	180
399-bp-ODN-Reference	GATCTTTCGAAAGGGCAGATTGTGTCGACAGGTAATGGTTGTCTGGTAAAAGGACAGGGC *****	180
Contig-399-15	CATCGCCAATTGGAGTATTTTGTGATAATGGTCTGCTAGTTGAACGGATCCATCTTCAA	239
contig-399-13	CATCGCCAATTGGAGTATTTTGTGATAATGGTCTGCTAGTTGAACGGATCCATCTTCAA	240
contig-399-26	CATCGCCAATTGGAGTATTTTGTGATAATGGTCTGCTAGTTGAACGGATCCATCTTCAA	240
399-bp-ODN-Reference	CATCGCCAATTGGAGTATTTTGTGATAATGGTCTGCTAGTTGAACGGATCCATCTTCAA *****	240
Contig-399-15	TGTTGTGGCGAATTTTGAAGTTAGCTTTGATTCCATCTTTTGTGTTGTCTGCCGTGATGT	299
contig-399-13	TGTTGTGGCGAATTTTGAAGTTAGCTTTGATTCCATCTTTTGTGTTGTCTGCCGTGATGT	300
contig-399-26	TGTTGTGGCGAATTTTGAAGTTAGCTTTGATTCCATCTTTTGTGTTGTCTGCCGTGATGT	300
399-bp-ODN-Reference	TGTTGTGGCGAATTTTGAAGTTAGCTTTGATTCCATCTTTTGTGTTGTCTGCCGTGATGT *****	300
Contig-399-15	ATACATTGTGTGAGTTATAGTTGTAAGTTGTAAGTTGTAAGTTGTAAGTTGTAAGTTGTAAGTT	359
contig-399-13	ATACATTGTGTGAGTTATAGTTGTAAGTTGTAAGTTGTAAGTTGTAAGTTGTAAGTTGTAAGTT	360
contig-399-26	ATACATTGTGTGAGTTATAGTTGTAAGTTGTAAGTTGTAAGTTGTAAGTTGTAAGTTGTAAGTT	360
399-bp-ODN-Reference	ATACATTGTGTGAGTTATAGTTGTAAGTTGTAAGTTGTAAGTTGTAAGTTGTAAGTTGTAAGTT *****	360
Contig-399-15	TAAAAATCAATACCTTTTAACTCGATACGATTAACAAGGG	398
contig-399-13	TAAAAATCAATACCTTTTAACTCGATACGATTAACAAGGG	399
contig-399-26	TAAAAATCAATACCTTTTAACTCGATACGATTAACAAGGG	399
399-bp-ODN-Reference	TAAAAATCAATACCTTTTAACTCGATACGATTAACAAGGG *****	399

contig-399-26: correct sequence

contig-399-15: one single-nucleotide (dA) deletion error

contig-399-13: one dG-to-dA substitution error

**401 bp ODN Alignments:** (The number after “contig-401-” is the lane number in Figure 3)

Contig-401-6	TATCACCTTCAAACCTGACTTCAGCACGCGTCTTGTAGTCCCGTCATCTTTGAAAGATA	60
contig-401-10	TATCACCTTCAAACCTGACTTCAGCACGCGTCTTGTAGTCCCGTCATCTTTGAAAGATA	60
401-bp-ODN-Reference	TATCACCTTCAAACCTGACTTCAGCACGCGTCTTGTAGTCCCGTCATCTTTGAAAGATA	60
Contig-401-20	TATCACCTTCAAACCTGACTTCAGCACGCGTCTTGTAGTCCCGTCATCTTTGAAAGATA *****	60
Contig-401-6	TAGTTCGTTCCCTGTACATAACCTTCGGGCATGGCACTCTTGAAAAAGTCATGCCGTTTCA	120
contig-401-10	TAGTTCGTTCCCTGTACATAACCTTCGGGCATGGCACTCTTGAAAAAGTCATGCCGTTTCA	120
401-bp-ODN-Reference	TAGTTCGTTCCCTGTACATAACCTTCGGGCATGGCACTCTTGAAAAAGTCATGCCGTTTCA	120
Contig-401-20	TAGTTCGTTCCCTGTACATAACCTTCGGGCATGGCACTCTTGAAAAAGTCATGCCGTTTCA **** *	120
Contig-401-6	TATGATCCGGATAACGGGAAAAGCATTGAACACCATAAGAGAAAAGTAGTGACAAGTGTG	180
contig-401-10	TATGATCCGGATAACGGGAAAAGCATTGAACACCATAAGAGAAAAGTAGTGACAAGTGTG	180
401-bp-ODN-Reference	TATGATCCGGATAACGGGAAAAGCATTGAACACCATAAGAGAAAAGTAGTGACAAGTGTG	180
Contig-401-20	TATGATCCGGATAACGGGAAAAGCATTGAACACCATAAGAGAAAAGTAGTGACAAGTGTG *****	180
Contig-401-6	GCCATGGAACAGGTAGTTTCCAGTAGTGCAAAATAAATTTAAGGGTAAGTTTCCGTATG	240
contig-401-10	GCCATGGAACAGGTAGTTTCCAGTAGTGCAAAATAAATTTAAGGGTAAGTTTCCGTATG	240
401-bp-ODN-Reference	GCCATGGAACAGGTAGTTTCCAGTAGTGCAAAATAAATTTAAGGGTAAGTTTCCGTATG	240
Contig-401-20	GCCATGGAACAGGTAGTTTCCAGTAGTGCAAAATAAATTTAAGGGTAAGTTTCCGTATG *****	240
Contig-401-6	TTGCATCACCTTACCCTCTCCACTGACAGAAAATTTGTGCCATTAAACATCAATCATCTA	299
contig-401-10	TTGCATCACCTTACCCTCTCCACTGACAGAAAATTTGTGCCATTAAACATCAATCATCTA	300
401-bp-ODN-Reference	TTGCATCACCTTACCCTCTCCACTGACAGAAAATTTGTGCCATTAAACATCAATCATCTA	300
Contig-401-20	TTGCATCACCTTACCCTCTCCACTGACAGAAAATTTGTGCCATTAAACATCAATCATCTA *****	300
Contig-401-6	ATTCAACAAGAATTGGGACAACCTCCAGTGAAAAGTCTTCTCCTTACTCATATTTTTTC	359
contig-401-10	ATTCAACAAGAATTGGGACAACCTCCAGTGAAAAGTCTTCTCCTTACTCATATTTTTTC	360
401-bp-ODN-Reference	ATTCAACAAGAATTGGGACAACCTCCAGTGAAAAGTCTTCTCCTTACTCATATTTTTTC	360
Contig-401-20	ATTCAACAAGAATTGGGACAACCTCCAGTGAAAAGTCTTCTCCTTACTCATATTTTTTC *****	360
Contig-401-6	CTCCTTATACTTAAGCCCTATAGTGAGTCGTATTAATTTCGC	400
contig-401-10	CTCCTTATACTTAAGCCCTATAGTGAGTCGTATTAATTTCGC	401
401-bp-ODN-Reference	CTCCTTATACTTAAGCCCTATAGTGAGTCGTATTAATTTCGC	401
Contig-401-20	CTCCTTATACTTAAGCCCTATAGTGAGTCGTATTAATTTCGC *****	401

contig-401-10: correct sequence

contig-401-6: one single-nucleotide (dC) deletion, and one dT-to-dC and one dG-to-dA substitution

contig-401-20: one dG-to-dA substitution

## 800 bp ODN Alignments:

GFP-from-synthesized-ODNs-1	TAAACCCCTCCGTTTTAGAGAGGGGTTATGCTAGTTATTTGTAGAGCTCATCCATGCCAT	60
GFP-from-synthesized-ODNs-2	TAAACCCCTCCGTTTTAGAGAGGGGTTATGCTAGTTATTTGTAGAGCTCATCCATGCCAT	60
GFP-from-commercial-ODN-1	TAAACCCCTCCGTTTTAGAGAGGGGTTATGCTAGTTATTTGTAGAGCTCATCCATGCCAT	60
800-bp-ODN-Reference	TAAACCCCTCCGTTTTAGAGAGGGGTTATGCTAGTTATTTGTAGAGCTCATCCATGCCAT	60
GFP-from-commercial-ODN-2	TAAACCCCTCCGTTTTAGAGAGGGGTTATGCTAGTTATTTGTAGAGCTCATCCATGCCAT	60
*****		
GFP-from-synthesized-ODNs-1	GTGTAATCCAGCAGCAGTTACAAACTCAAGAAGGACCATGTGGTCACGCTTTTCGTTGG	120
GFP-from-synthesized-ODNs-2	GTGTAATCCAGCAGCAGTTACAAACTCAAGAAGGACCATGTGGTCACGCTTTTCGTTGG	120
GFP-from-commercial-ODN-1	GTGTAATCCAGCAGCAGTTACAAACTCAAGAAGGACCATGTGGTCACGCTTTTCGTTGG	120
800-bp-ODN-Reference	GTGTAATCCAGCAGCAGTTACAAACTCAAGAAGGACCATGTGGTCACGCTTTTCGTTGG	120
GFP-from-commercial-ODN-2	GTGTAATCCAGCAGCAGTTACAAACTCAAGAAGGACCATGTGGTCACGCTTTTCGTTGG	120
*****		
GFP-from-synthesized-ODNs-1	GATCTTTCGAAAGGGCAGATTGTGTCGACAGGTAATGGTGTCTGGTAAAAGGACAGGGC	180
GFP-from-synthesized-ODNs-2	GATCTTTCGAAAGGGCAGATTGTGTCGACAGGTAATGGTGTCTGGTAAAAGGACAGGGC	180
GFP-from-commercial-ODN-1	GATCTTTCGAAAGGGCAGATTGTGTCGACAGGTAATGGTGTCTGGTAAAAGGACAGGGC	180
800-bp-ODN-Reference	GATCTTTCGAAAGGGCAGATTGTGTCGACAGGTAATGGTGTCTGGTAAAAGGACAGGGC	180
GFP-from-commercial-ODN-2	GATCTTTCGAAAGGGCAGATTGTGTCGACAGGTAATGGTGTCTGGTAAAAGGACAGGGC	180
*****		
GFP-from-synthesized-ODNs-1	CATCGCCAATTGGAGTATTTTGTGATAATGGTCTGCTAGTTGAACGGATCCATCTTCAA	240
GFP-from-synthesized-ODNs-2	CATCGCCAATTGGAGTATTTTGTGATAATGGTCTGCTAGTTGAACGGATCCATCTTCAA	240
GFP-from-commercial-ODN-1	CATCGCCAATTGGAGTATTTTGTGATAATGGTCTGCTAGTTGAACGGATCCATCTTCAA	240
800-bp-ODN-Reference	CATCGCCAATTGGAGTATTTTGTGATAATGGTCTGCTAGTTGAACGGATCCATCTTCAA	240
GFP-from-commercial-ODN-2	CATCGCCAATTGGAGTATTTTGTGATAATGGTCTGCTAGTTGAACGGATCCATCTTCAA	240
*****		
GFP-from-synthesized-ODNs-1	TGTTGTGGCGAATTTTGAAGTTAGCTTTGATTCCATTCCTTTTGTGTCTGCCGTGATGT	300
GFP-from-synthesized-ODNs-2	TGTTGTGGCGAATTTTGAAGTTAGCTTTGATTCCATTCCTTTTGTGTCTGCCGTGATGT	300
GFP-from-commercial-ODN-1	TGTTGTGGCGAATTTTGAAGTTAGCTTTGATTCCATTCCTTTTGTGTCTGCCGTGATGT	300
800-bp-ODN-Reference	TGTTGTGGCGAATTTTGAAGTTAGCTTTGATTCCATTCCTTTTGTGTCTGCCGTGATGT	300
GFP-from-commercial-ODN-2	TGTTGTGGCGAATTTTGAAGTTAGCTTTGATTCCATTCCTTTTGTGTCTGCCGTGATGT	300
*****		
GFP-from-synthesized-ODNs-1	ATACATTTGTGAGTTATAGTTGTAAGTTGACTCGAGTTTGTGTCGAGAAATGTTCCATCTTCTT	360
GFP-from-synthesized-ODNs-2	ATACATTTGTGAGTTATAGTTGTAAGTTGACTCGAGTTTGTGTCGAGAAATGTTCCATCTTCTT	360
GFP-from-commercial-ODN-1	ATACATTTGTGAGTTATAGTTGTAAGTTGACTCGAGTTTGTGTCGAGAAATGTTCCATCTTCTT	360
800-bp-ODN-Reference	ATACATTTGTGAGTTATAGTTGTAAGTTGACTCGAGTTTGTGTCGAGAAATGTTCCATCTTCTT	360
GFP-from-commercial-ODN-2	ATACATTTGTGAGTTATAGTTGTAAGTTGACTCGAGTTTGTGTCGAGAAATGTTCCATCTTCTT	360
*****		
GFP-from-synthesized-ODNs-1	TAAAAATCAATACCTTTTAACTCGATACGATTAACAAGGGTATCACCTTCAAACCTTGACTT	420
GFP-from-synthesized-ODNs-2	TAAAAATCAATACCTTTTAACTCGATACGATTAACAAGGGTATCACCTTCAAACCTTGACTT	420
GFP-from-commercial-ODN-1	TAAAAATCAATACCTTTTAACTCGATACGATTAACAAGGGTATCACCTTCAAACCTTGACTT	420
800-bp-ODN-Reference	TAAAAATCAATACCTTTTAACTCGATACGATTAACAAGGGTATCACCTTCAAACCTTGACTT	420
GFP-from-commercial-ODN-2	TAAAAATCAATACCTTTTAACTCGATACGATTAACAAGGGTATCACCTTCAAACCTTGACTT	420
*****		
GFP-from-synthesized-ODNs-1	CAGCACGCGTCTTGTAGTTCCCGTCATCTTTGAAAGATATAGTGCCTTCTGTACATAAC	480
GFP-from-synthesized-ODNs-2	CAGCACGCGTCTTGTAGTTCCCGTCATCTTTGAAAGATATAGTGCCTTCTGTACATAAC	480
GFP-from-commercial-ODN-1	CAGCACGCGTCTTGTAGTTCCCGTCATCTTTGAAAGATATAGTGCCTTCTGTACATAAC	480
800-bp-ODN-Reference	CAGCACGCGTCTTGTAGTTCCCGTCATCTTTGAAAGATATAGTGCCTTCTGTACATAAC	480
GFP-from-commercial-ODN-2	CAGCACGCGTCTTGTAGTTCCCGTCATCTTTGAAAGATATAGTGCCTTCTGTACATAAC	480
*****		
GFP-from-synthesized-ODNs-1	CTTCGGGCATGGCACCTTTGAAAAAGTCATGCCGTTTCATATGATCCGGATAACCGGAAA	540
GFP-from-synthesized-ODNs-2	CTTCGGGCATGGCACCTTTGAAAAAGTCATGCCGTTTCATATGATCCGGATAACCGGAAA	540
GFP-from-commercial-ODN-1	CTTCGGGCATGGCACCTTTGAAAAAGTCATGCCGTTTCATATGATCCGGATAACCGGAAA	540
800-bp-ODN-Reference	CTTCGGGCATGGCACCTTTGAAAAAGTCATGCCGTTTCATATGATCCGGATAACCGGAAA	540
GFP-from-commercial-ODN-2	CTTCGGGCATGGCACCTTTGAAAAAGTCATGCCGTTTCATATGATCCGGATAACCGGAAA	540
*****		
GFP-from-synthesized-ODNs-1	AGCATTGAACACCATAAGAGAAAGTAGTGACAAGTGTGGCCATGGAACAGGTAGTTTTTC	600
GFP-from-synthesized-ODNs-2	AGCATTGAACACCATAAGAGAAAGTAGTGACAAGTGTGGCCATGGAACAGGTAGTTTTTC	600
GFP-from-commercial-ODN-1	AGCATTGAACACCATAAGAGAAAGTAGTGACAAGTGTGGCCATGGAACAGGTAGTTTTTC	600
800-bp-ODN-Reference	AGCATTGAACACCATAAGAGAAAGTAGTGACAAGTGTGGCCATGGAACAGGTAGTTTTTC	600
GFP-from-commercial-ODN-2	AGCATTGAACACCATAAGAGAAAGTAGTGACAAGTGTGGCCATGGAACAGGTAGTTTTTC	600
*****		
GFP-from-synthesized-ODNs-1	CAGTAGTGCAAAATAAATTTAAGGGTAAGTTTTCCGTATGTTGCATCACCTTCAACCTCTC	660
GFP-from-synthesized-ODNs-2	CAGTAGTGCAAAATAAATTTAAGGGTAAGTTTTCCGTATGTTGCATCACCTTCAACCTCTC	660
GFP-from-commercial-ODN-1	CAGTAGTGCAAAATAAATTTAAGGGTAAGTTTTCCGTATGTTGCATCACCTTCAACCTCTC	660
800-bp-ODN-Reference	CAGTAGTGCAAAATAAATTTAAGGGTAAGTTTTCCGTATGTTGCATCACCTTCAACCTCTC	660
GFP-from-commercial-ODN-2	CAGTAGTGCAAAATAAATTTAAGGGTAAGTTTTCCGTATGTTGCATCACCTTCAACCTCTC	660
*****		

GFP-from-synthesized-ODNs-1	CACTGACAGAAAATTTGTGCCCATTAACATCACCATCTAATTCACAAGAATTGGGACAA	720
GFP-from-synthesized-ODNs-2	CACTGACAGAAAATTTGTGCCCATTAACATCACCATCTAATTCACAAGAATTGGGACAA	720
GFP-from-commercial-ODN-1	CACTGACAGAAAATTTGTGCCCATTAACATCACCATCTAATTCACAAGAATTGGGACAA	720
800-bp-ODN-Reference	CACTGACAGAAAATTTGTGCCCATTAACATCACCATCTAATTCACAAGAATTGGGACAA	720
GFP-from-commercial-ODN-2	CACTGACAGAAAATTTGTGCCCATTAACATCACCATCTAATTCACAAGAATTGGGACAA	720
	*****	
GFP-from-synthesized-ODNs-1	CTCCAGTGAAAAGTTCCTCCTTTACTCATATTTTTCTCCTTATACTTAAGCCCTAT	780
GFP-from-synthesized-ODNs-2	CTCCAGTGAAAAGTTCCTCCTTTACTCATATTTTTCTCCTTATACTTAAGCCCTAT	780
GFP-from-commercial-ODN-1	CTCCAGTGAAAAGTTCCTCCTTTACTCATATTTTTCTCCTTATACTTAAGCCCTAT	780
800-bp-ODN-Reference	CTCCAGTGAAAAGTTCCTCCTTTACTCATATTTTTCTCCTTATACTTAAGCCCTAT	780
GFP-from-commercial-ODN-2	CTCCAGTGAAAAGTTCCTCCTTTACTCATATTTTTCTCCTTATACTTAAGCCCTAT	780
	*****	
GFP-from-synthesized-ODNs-1	AGTGAGTCGTATTAATTCGC	800
GFP-from-synthesized-ODNs-2	AGTGAGTCGTATTAATTCGC	800
GFP-from-commercial-ODN-1	AGTGAGTCGTATTAATTCGC	800
800-bp-ODN-Reference	AGTGAGTCGTATTAATTCGC	800
GFP-from-commercial-ODN-2	AGTGAGTCGTATTAATTCGC	800
	*****	

The two GFP genes from synthesized ODNs are correct. For the two control GFP genes from commercial ODN, one is correct, and the other has a dG-to-dA substitution error.

## References

1. Azhayev, A.; Gouzaev, A.; Hovinen, J.; Azhayeva, E.; Lonnberg, H. Analogs of oligonucleotides containing 3'-deoxy- $\beta$ -D-Psicothymidine. *Tetrahedron Lett.*, **1993**, *34*, 6435-6438.
2. Pokharel, D.; Fang, S. Y. Polymerizable phosphoramidites with an acid-cleavable linker for eco-friendly synthetic oligodeoxynucleotide purification. *Green Chem.*, **2016**, *18*, 1125-1136.